← Leaderboards
Paul C Marker
University Of Minnesota Twin Cities
$5,910,239
Attributed
$6,229,016
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $662.9K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,229,016 · 8
By mechanism
R01$4,559,427 · 3
R21$1,032,035 · 3
U54$637,554 · 2
Top collaborators
- Jill A. Macoska5 shared
Others in their field
Top investigators on “Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$257,543,614
- Charles A Coltman · Southwest Oncology Group$181,133,593
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Larry Arthur$62,719,328
- William J. Blot · Vanderbilt University$62,640,427
- Walter John Curran · Thomas Jefferson University$60,981,384
Research focus
ProstateIn VitroBaseProstaticPathway InteractionsMolecularSignal TransductionResponseIn VivoResearch StudySamplingGrowthMalignant Neoplasm Of ProstatePublishingInhibitor/AntagonistProteinsTissuesPhenotypeGeneticPathologyLeadProstatic NeoplasmsGenesProtein Isoforms
Grant awards (26)
Persistence of an IL-4/IL-13 autocrine loop promotes fibrosis-mediated urinary voiding dysfunction$126,949
U54 · FY2023 · DK · contact PI
Persistence of an IL-4/IL-13 autocrine loop promotes fibrosis-mediated urinary voiding dysfunction$126,949
U54 · FY2022 · DK · contact PI
Growth hormone actions in prostate carcinogenesis$206,962
R21 · FY2021 · CA · contact PI
Persistence of an IL-4/IL-13 autocrine loop promotes fibrosis-mediated urinary voiding dysfunction$126,950
U54 · FY2021 · DK · contact PI
Growth hormone actions in prostate carcinogenesis$171,242
R21 · FY2020 · CA · contact PI
Persistence of an IL-4/IL-13 autocrine loop promotes fibrosis-mediated urinary voiding dysfunction$90,335
U54 · FY2020 · DK · contact PI
Persistence of an IL-4/IL-13 autocrine loop promotes fibrosis-mediated urinary voiding dysfunction$166,371
U54 · FY2019 · DK · contact PI
Magi2 in aggressive prostate cancer$195,054
R21 · FY2017 · CA · contact PI
Magi2 in aggressive prostate cancer$161,777
R21 · FY2016 · CA · contact PI
Steroid hormones and SFRP1 in the age-related incidence of BPH and BOO$322,245
R01 · FY2015 · DK · contact PI
Steroid hormones and SFRP1 in the age-related incidence of BPH and BOO$322,245
R01 · FY2014 · DK · contact PI
Novel prostate cancer oncogenes identified by transposon mutagenesis$286,436
R01 · FY2014 · CA · contact PI
Steroid hormones and SFRP1 in the age-related incidence of BPH and BOO$310,966
R01 · FY2013 · DK · contact PI
Novel prostate cancer oncogenes identified by transposon mutagenesis$277,682
R01 · FY2013 · CA · contact PI
Steroid hormones and SFRP1 in the age-related incidence of BPH and BOO$322,245
R01 · FY2012 · DK · contact PI
Novel prostate cancer oncogenes identified by transposon mutagenesis$294,345
R01 · FY2012 · CA · contact PI
Steroid hormones and SFRP1 in the age-related incidence of BPH and BOO$371,250
R01 · FY2011 · DK · contact PI
Novel prostate cancer oncogenes identified by transposon mutagenesis$291,634
R01 · FY2011 · CA · contact PI
Novel prostate cancer oncogenes identified by transposon mutagenesis$297,941
R01 · FY2010 · CA · contact PI
Genetic Analysis of a Prostate Tumor Suppressor Region$286,786
R01 · FY2010 · AG · contact PI
Genetic Analysis of a Prostate Tumor Suppressor Region$289,683
R01 · FY2009 · AG · contact PI
Genetic Analysis of a Prostate Tumor Suppressor Region$289,683
R01 · FY2008 · AG · contact PI
Genetic Analysis of a Prostate Tumor Suppressor Region$297,587
R01 · FY2007 · AG · contact PI
Genetic Analysis of a Prostate Tumor Suppressor Region$298,699
R01 · FY2006 · AG · contact PI
Identification of prostate-specific regulation elements$148,500
R21 · FY2005 · DK
Identification of prostate-specific regulation elements$148,500
R21 · FY2004 · DK